Calliditas Therapeutics AB
CALT
|
$18.5
1.65%
1.62%
1.5K
|
Health Technology
(0.0% 1d) (-15.3% 1m) (-24.1% 1y) (0.0% 2d) (1.6% 3d) (-1.1% 7d) (-22.85% volume)
Earnings Calendar:
Market Cap: $ 551,115,814
http://www.calliditas.se
Sec Filling | Patents | 16 employees
Calliditas Therapeutics AB provides pharmaceutical products for patients with niche indications. It focuses on development and commercialization of the product candidate Nefecon intended for treatment of patients with the inflammatory renal disease IgA nephropathy. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.
renal nephropathy treatment iga nephropathy
add to watch list Paper trade email alert is off
Press-releases
Calliditas Announces Positive NefIgArd Open Label Extension Results
Published: 2024-04-24 (Crawled : 08:00) - prnewswire.com
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: 3.46%
H: 0.0%
C: -1.75%
label positive nefigard extension results
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: -0.87%
H: 3.58%
C: -2.86%
nephropathy congress world nefecon trial therapeutics
Calliditas Therapeutics to Attend Conferences in April
Published: 2024-04-09 (Crawled : 13:00) - biospace.com/
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: 6.93%
H: 0.0%
C: -2.17%
therapeutics
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
Published: 2024-04-08 (Crawled : 12:30) - prnewswire.com
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: -1.06%
H: 3.5%
C: 0.51%
congress world nefecon therapeutics
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
Published: 2024-04-08 (Crawled : 09:00) - biospace.com/
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: -1.06%
H: 3.5%
C: 0.51%
patent cancer treatment for application
Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients
Published: 2024-03-20 (Crawled : 01:00) - prnewswire.com
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: 1.43%
H: 0.0%
C: 0.0%
nefegan nephropathy health treatment sciences
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer
Published: 2024-03-18 (Crawled : 01:00) - prnewswire.com
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: -4.04%
H: 3.27%
C: 3.04%
management medical
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
Published: 2024-03-12 (Crawled : 02:00) - prnewswire.com
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: 1.48%
H: 0.44%
C: -2.26%
nefecon fda drug grants therapeutics
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
Published: 2024-03-06 (Crawled : 08:00) - prnewswire.com
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: 13.42%
H: 0.22%
C: -4.35%
tarpeyo drug year
Calliditas Year-end report, January - December 2023
Published: 2024-02-21 (Crawled : 07:00) - prnewswire.com
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: -3.06%
H: 3.8%
C: 0.1%
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10